Journal of the Canadian Association of Gastroenterology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
A262 NEONATAL ACUTE LIVER FAILURE DUE TO PRESUMED GESTATIONAL ALLOIMMUNE LIVER DISEASE - A CASE REPORT
2023
-
A168 KAISO-INDUCED INTESTINAL INFLAMMATION IS ACCOMPANIED BY FAULTY CELL ADHESION AND ABERRANT INTESTINAL REPAIR.
2018
-
Role of serotonin-autophagy axis in regulation of epithelial cell function and microbiota composition in gut.
-
Is the microbiome important in celiac disease?.
8:S51-S55.
2025
-
A1 BACTERIAL LYSOPHOSPHATIDYLCHOLINE (LPC) AND LYSOPHOSPHATIDIC ACID (LPA) INDUCE VISCERAL HYPERSENSITIVITY THROUGH TRANSIENT RECEPTOR POTENTIAL CANONICAL 5 (TRPC5) AND LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) AND 3 (LPAR3) DEPENDENT-MECHANISMS.
8:i1-i1.
2025
-
A10 RESTORATION OF ARYL HYDROCARBON RECEPTOR SIGNALING IN CELIAC DISEASE BY ORAL TRYPTOPHAN SUPPLEMENTATION: AN EXPLORATORY STUDY.
8:i6-i6.
2025
-
A105 TRANSITION TO ADULTHOOD THROUGH COACHING AND EMPOWERMENT (TRACE): A FEASIBILITY RCT.
8:i41-i42.
2025
-
A106 PATIENTS’ BARRIERS TO OPTIMIZING DIETARY INTERVENTIONS IN INFLAMMATORY BOWEL DISEASE (IBD): A DESCRIPTIVE QUALITATIVE STUDY.
8:i42-i42.
2025
-
A130 EVALUATING PLACEBO RATES IN EOSINOPHILIC ESOPHAGITIS RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
8:i51-i52.
2025
-
A149 LYTIC PHAGE REDUCES COLITIS SEVERITY IN MICE COLONIZED WITH IBD-ASSOCIATED E. COLI NRG857C.
8:i61-i62.
2025
-
A156 FECAL PROTEOLYTIC ACTIVITY IS ASSOCIATED WITH SYMPTOMATIC STATUS IN CROHN’S DISEASE.
8:i64-i64.
2025
-
A23 INVESTIGATING THE LINK OF BACTERIAL TRANSLOCATION AND BEHAVIORAL CHANGES IN A MOUSE RESTRAINT STRESS MODEL.
8:i9-i10.
2025
-
A4 SACCHAROMYCES BOULARDII CNCM I-745 ENHANCES DUODENAL MICROBIOTA-MEDIATED TRYPTOPHAN METABOLISM IMPROVING GLUTEN IMMUNOPATHOLOGY.
8:i3-i3.
2025
-
A43 TOPICAL HEMOSTATIC AGENTS: A POTENTIAL BREAKTHROUGH IN MALIGNANCY-RELATED GI BLEEDING? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.
8:i17-i17.
2025
-
A56 THE ROLE OF THE STERILE ALPHA MOTIF (SAM) POINTED DOMAIN ETS FAMILY TRANSCRIPTION FACTOR (SPDEF) ON GOBLET CELL BIOLOGY AND INTESTINAL MUCUS PRODUCTION IN THE CONTEXT OF PARASITIC HOST DEFENSE..
8:i23-i23.
2025
-
A57 SUBOPTIMAL FIBRE CONSUMPTION AND ALTERED FIBRE METABOLISM IN CELIAC DISEASE THROUGHOUT THE GASTROINTESTINAL TRACT.
8:i23-i23.
2025
-
A6 INVESTIGATING THE RELATIONSHIP BETWEEN MUCOSAL INFLAMMATION AND PROTEOLYTIC ACTIVITY IN CROHN’S DISEASE.
8:i3-i3.
2025
-
A62 UNCOVERING MICROBIAL DETERMINANTS OF IBS FLARE-UPS: COHORT-LEVEL VS PATIENT-SPECIFIC APPROACHES.
8:i25-i25.
2025
-
A70 EXPLORING THE ROLE OF MICROBIAL PHOSPHOLIPIDS IN VISCERAL HYPERSENSITIVITY AND ALTERED EMOTIONAL BEHAVIOUR INDUCED BY INFLAMMATORY BOWEL DISEASE (IBD)-ASSOCIATED MICROBIOTA.
8:i28-i28.
2025
-
A96 WHICH IS THE BEST ENDOSCOPIC HEMOSTATIC THERAPY FOR DIEULAFOY’S LESIONS? A SYSTEMATIC REVIEW AND META-ANALYSIS.
8:i37-i37.
2025
-
Sustainable practice in gastroenterology: travel-related CO2 emissions for gastroenterology clinic appointments in Canada..
8:7-12.
2025
-
Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease..
7:423-430.
2024
-
Response from the Canadian Children Inflammatory Bowel Disease Network to the US Food and Drug Administration Draft Guidance for Industry on pediatric inflammatory bowel disease: developing drugs for treatment..
7:397-398.
2024
-
Canadian colorectal cancer screening programs: How do they measure up using the International Agency for Research on Cancer criteria for organized screening?.
7:312-318.
2024
-
The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study..
7:290-298.
2024
-
Inpatient Screening, Brief Intervention, and Referral to Treatment for Alcohol Use Disorder in Patients Admitted with Alcohol-associated Liver Disease Is Not Universally Implemented in Practice, But Can Reduce Readmissions for Alcohol-associated Hepatitis.
7:169-176.
2024
-
Measuring the Impact of Patient Engagement in Health Research: An Exploratory Study Using Multiple Survey Tools.
7:177-187.
2024
-
The Canadian Association of Gastroenterology’s New Climate Change Committee.
7:135-136.
2024
-
A113 COVID-19 VACCINATIONS IN IBD PATIENTS: PATIENT KNOWLEDGE AND PERCEPTIONS.
7:85-85.
2024
-
A13 MICROBIOTA FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) INDUCE ALTERED BEHAVIOUR AND VISCERAL HYPERSENSITIVITY IN MICROBIOTA-HUMANIZED MICE.
7:7-7.
2024
-
A15 LEVERAGING CULTURE-DEPENDENT AND -INDEPENDENT METAGENOMICS TO IDENTIFY ENTEROBACTERIACEAE GENES ASSOCIATED WITH ACTIVE ULCERATIVE COLITIS.
7:8-9.
2024
-
A176 RESTORATION OF IMPAIRED MICROBIOTA-MEDIATED ARYL HYDROCARBON RECEPTOR SIGNALING IN PATIENTS WITH CELIAC DISEASE BY ORAL TRYPTOPHAN SUPPLEMENTATION: AN EXPLORATORY STUDY.
7:138-139.
2024
-
A187 PROPHYLACTIC PHAGE TREATMENT ENHANCES SUB-THERAPEUTIC EFFICACY OF BUDESONIDE AGAINST E. COLI DRIVEN COLITIS IN MICE COLONIZED WITH A DEFINED MICROBIOTA.
7:147-148.
2024
-
A189 INVESTIGATING THE ROLE OF BACTERIAL HISTAMINE METABOLISM IN VISCERAL HYPERALGESIA.
7:148-149.
2024
-
A19 THE IMPACT OF FOOD INSECURITY ON ADHERENCE TO A GLUTEN-FREE DIET IN THE ADULT CELIAC DISEASE POPULATION ATTENDING A DEDICATED CELIAC CLINIC.
7:10-11.
2024
-
A200 EXPOSURE TO CANNABIS SMOKE IN UTERO AFFECTS THE DEVELOPMENT OF THE ENDOCANNABINOID SYSTEM IN THE GASTROINTESTINAL TRACT.
7:157-158.
2024
-
A22 INVESTIGATING THE EFFECTS OF DIET TRIGGER DISCLOSURE ON BEHAVIOUR IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH PERCEIVED GLUTEN SENSITIVITY.
7:12-13.
2024
-
A24 AN ULCERATIVE COLITIS-ISOLATED PATHOBIONT CAN DEGRADE MUCUS PRODUCED BY UC PATIENT-DERIVED COLONOIDS.
7:13-14.
2024
-
A246 EXAMINING BARRIERS TO PHYSICAL ACTIVITY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS.
7:198-198.
2024
-
A265 BARRIERS TO DIETARY MODIFICATION IN INFLAMMATORY BOWEL DISEASE (IBD): A MIXED-METHODS ASSESSMENT OF PATIENT PERCEPTIONS.
7:213-214.
2024
-
A303 SAFETY AND EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH LIVER CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
7:246-247.
2024
-
A312 FACTORS ASSOCIATED WITH PHYSICAL SYMPTOM BURDEN AMONG PATIENTS WITH PANCREATIC CANCER.
7:254-254.
2024
-
A36 EFFECT OF FIBRE SUPPLEMENTATION IN CELIAC DISEASE: IMPLICATIONS FOR MUCOSAL HEALING.
7:20-21.
2024
-
A41 IDENTIFICATION OF MICROBIAL LYSOPHOSPHATIDYLCHOLINE (LPC) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCERS AND THEIR EFFECTS ON THE HOST.
7:24-25.
2024
-
A42 A HIGH SALT DIET INCREASES ELASTOLYTIC ACTIVITY AND WORSENS COLITIS IN GNOTOBIOTIC MICE.
7:25-25.
2024
-
A6 LYSOPHOSPHATIDYLCHOLINE (LPC) AND LYSOPHOSPHATIDIC ACID (LPA) INDUCE VISCERAL HYPERSENSITIVITY IN IRRITABLE BOWEL SYNDROME (IBS).
7:3-4.
2024
-
A63 RESTRAINED STRESS IN MICE INDUCES TRANSLOCATION OF GUT COMMENSAL BACTERIAL INTO DISTAL ORGANS.
7:42-43.
2024
-
A73 EVALUATING MENTAL HEALTH CONDITIONS IN YOUTH WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY.
7:50-50.
2024
-
A81 GASTROINTESTINAL (GI) FEATURES OF HYPERMOBILE EHLERS-DANLOS SYNDROME (HEDS) AND HYPERMOBILITY SPECTRUM DISORDER (HSD): A SCOPING REVIEW.
7:56-57.
2024
-
Emerging Roles of Gut Serotonin in Regulation of Immune Response, Microbiota Composition and Intestinal Inflammation.
7:88-96.
2024
-
A312 FACTORS ASSOCIATED WITH PHYSICAL SYMPTOM BURDEN AMONG PATIENTS WITH PANCREATIC CANCER.
7:254-254.
2024
-
Understanding Predictors of Crohn's Disease: Determinants of Altered Barrier Function in Pre-Disease Phase of Crohn's Disease..
7:68-77.
2024
-
Review and Critical Appraisal of Clinical Practice Guidelines of Modalities Used in the Diagnosis of Celiac Disease.
6:106-114.
2023
-
A13 THE RATE OF ADVERSE EVENTS AFTER COVID-19 VACCINATION IS SIMILAR IN PATIENTS WITH CELIAC DISEASE AND NON-CELIAC POPULATION: RESULTS OF A LARGE INTERNATIONAL CROSS-SECTIONAL STUDY.
6:7-8.
2023
-
A19 INVESTIGATING MECHANISMS THAT DRIVE SYMPTOMS IN IRRITABLE BOWEL SYNDROME PATIENTS WITH PERCEIVED GLUTEN SENSITIVITY.
6:10-11.
2023
-
A265 TEMPORAL DYNAMICS OF SYMPTOMS AND GUT MICROBIOTA IN EPISODES OF IRRITABLE BOWEL SYNDROME.
6:83-83.
2023
-
A266 DIET-BASED THERAPIES FOR INTESTINAL DYSFUNCTION INDUCED BY CLOSTRIDIOIDES DIFFICILE INFECTION.
6:83-84.
2023
-
A267 IDENTIFYING ENTEROBACTERIACEAE VIRULENCE GENES ASSOCIATED WITH ACTIVE DISEASE IN ULCERATIVE COLITIS PATIENTS USING CULTURE-DEPENDENT AND -INDEPENDENT APPROACHES.
6:84-85.
2023
-
A276 CANNABINOID RECEPTOR 1 IS LOCALIZED IN ENTERIC NEURONS AND EPITHELIUM IN FETAL AND EARLY POSTNATAL MOUSE INTESTINE.
6:90-90.
2023
-
A3 CROHN’S DISEASE PROTEOLYTIC MICROBIOTA ENHANCES INFLAMMATION THROUGH PAR2 PATHWAY IN GNOTOBIOTIC MICE.
6:2-2.
2023
-
A32 PHAGE TREATMENT DELAYS ONSET OF CROHN’S-ASSOCIATED E. COLI DRIVEN COLITIS IN MICE COLONIZED WITH A DEFINED MICROBIOTA.
6:17-18.
2023
-
A33 EFFECTS OF THE NEXT GENERATION PROBIOTIC, AKKERMANSIA MUCINIPHILA, ON INTESTINAL INFLAMMATION AND BARRIER FUNCTION.
6:18-18.
2023
-
A45 FIBER-FREE DIET REDUCES BACTEROIDES ABUNDANCE AND PREVENTS MUCUS DEGRADATION IN MICE COLONIZED WITH MICROBIOTA FROM PATIENTS WITH GENERALIZED ANXIETY DISORDER.
6:25-26.
2023
-
A53 FECAL BIOACTIVE PHOSPHOLIPIDS AS TRIGGERS OF INTESTINAL HYPERSENSITIVITY IN IRRITABLE BOWEL SYNDROME.
6:29-30.
2023
-
A56 DEVELOPMENT OF A PROGNOSTIC SURVIVAL MODEL FOR PATIENTS DIAGNOSED WITH PANCREATIC CANCER IN ONTARIO.
6:31-31.
2023
-
A62 IDENTIFICATION OF SPECIFIC COLONIC DEEP MUSCLE LAYER MACROPHAGES SUBSETS BY THE CD64 (FCΓRI) MARKER.
6:34-34.
2023
-
A7 OPPORTUNISTIC PATHOGEN MODULATION OF GLUTEN-REACTIVE CD4+ T CELL ACTIVATION BY DQ2-EXPRESSING ORGANOID MONOLAYERS.
6:4-4.
2023
-
A8 MICROBIAL ACTIVATION OF INTESTINAL DENDRITIC CELLS IS CRITICAL FOR THE ESTABLISHMENT OF NORMAL BEHAVIOR.
6:4-5.
2023
-
A87 PERSPECTIVES ON DIET MODIFICATION TO MANAGE THEIR SYMPTOMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. A SCOPING REVIEW.
6:47-48.
2023
-
A262 NEONATAL ACUTE LIVER FAILURE DUE TO PRESUMED GESTATIONAL ALLOIMMUNE LIVER DISEASE - A CASE REPORT.
6:81-82.
2023
-
A56 DEVELOPMENT OF A PROGNOSTIC SURVIVAL MODEL FOR PATIENTS DIAGNOSED WITH PANCREATIC CANCER IN ONTARIO.
6:31-31.
2023
-
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response.
5:208-213.
2022
-
Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn’s and Colitis Canada.
5:105-115.
2022
-
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period.
5:100-101.
2022
-
Comparative Effectiveness of Lumen-Apposing Metal Stents and Plastic Stents for the Treatment of Pancreatic Walled-Off Necrosis: A Meta-analysis.
5:68-78.
2022
-
A10 EARLY LIFE SENSITIZATION TO GLUTEN INDUCES SUSTAINED IMMUNOPATHOLOGY IN DR3-DQ2 MICE.
5:11-13.
2022
-
A13 GUT MICROBIOTA MODULATES CGRP PRODUCTION BY DRG NEURONS IN FEMALE MICE.
5:15-17.
2022
-
A14 THE INTESTINAL MICROBIOTA CONTRIBUTES TO AGE-RELATED MEMORY DECLINE.
5:17-18.
2022
-
A144 CHRONIC DSS LEADS TO ALTERED EXPRESSION OF IRAK4/TPL2 PATHWAYS IN UC-COLONIZED MICE.
5:17-18.
2022
-
A191 PERSISTENT BENEFIT OF DIETITIAN-LED GLUTEN-FREE DIET EDUCATION AT CD DIAGNOSIS ON DIETARY ADHERENCE IN CHILDREN AND ADULTS WITH TYPE 1 DIABETES AND CELIAC DISEASE.
5:75-76.
2022
-
A192 CONSUMPTION OF FOOD LOWER IN TRYPTOPHAN IS ASSOCIATED WITH SIGNIFICANT ANXIETY IN PATIENTS WITH CELIAC DISEASE.
5:76-77.
2022
-
A194 THE ADDITION OF DEAMIDATED GLIADIN PEPTIDE TO TISSUE TRANSGLUTAMINASE ANTIBODIES DOES NOT INCREASE THE ODDS OF CELIAC DISEASE DIAGNOSIS IN AN IGA SUFFICIENT POPULATION.
5:79-80.
2022
-
A196 DIARRHEA AS A PRESENTING SYMPTOM OF RELAPSED GRANULOMATOSIS WITH POLYANGIITIS.
5:81-82.
2022
-
A200 CROHN’S-ASSOCIATED E. COLI WORSEN COLITIS SEVERITY IN MICE COLONIZED WITH DEFINED MICROBIOTA.
5:85-86.
2022
-
A227 THE EFFECTIVENESS OF PEG 3350 COMPARED TO LACTULOSE FOR THE TREATMENT OF ACUTE HEPATIC ENCEPHALOPATHY IN ADULT CIRRHOTIC PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
5:118-119.
2022
-
A229 GUT MICROBIOTA PROFILES, DIET AND SHORT-CHAIN FATTY ACIDS AS PREDICTORS OF GENERALIZED ANXIETY DISORDER.
5:120-121.
2022
-
A241 KIWIFRUIT AND KIWIFRUIT EXTRACTS FOR TREATMENT OF CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
5:133-134.
2022
-
A246 GASTROINTESTINAL ADVERSE EVENTS OF CANNABINOIDS IN PEDIATRIC POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
5:138-139.
2022
-
A248 THE ROLE OF DIETARY TRYPTOPHAN IN INDOLE AND KYNURENINE PRODUCTION AND IMMUNE MODULATION IN HEALTHY INDIVIDUALS.
5:141-142.
2022
-
A34 GLUTEN-FREE DIET IMPROVES DYSPEPTIC SYMPTOMS IN PATIENTS WITH TYPE 1 DIABETES IN WHOM CELIAC DISEASE WAS EXCLUDED.
5:40-41.
2022
-
A46 BIOGEOGRAPHIC VARIATION AND FUNCTIONAL PATHWAYS OF THE GUT MICROBIOTA IN CELIAC DISEASE.
5:53-54.
2022
-
A5 GLUTEN-SPECIFIC T CELL ACTIVATION BY MHC CLASS II EXPRESSING ORGANOID MONOLAYERS.
5:6-6.
2022
-
A51 ROLE OF GUT MICROBIOTA IN THE EPISODIC NATURE OF SYMPTOMS IN IRRITABLE BOWEL SYNDROME.
5:58-60.
2022
-
A6 MECHANISMS UNDERLYING GUT DYSFUNCTION FOLLOWING C. DIFFICILE INFECTION AND IMPLICATIONS FOR TREATMENT.
5:6-8.
2022
-
A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES.
5:76-77.
2022
-
A68 THERAPEUTIC EFFECTS OF MEDICINAL CANNABINOIDS ON THE GASTROINTESTINAL SYSTEM IN PEDIATRIC PATIENTS: A SYSTEMATIC REVIEW.
5:78-79.
2022
-
A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES.
5:76-77.
2022
-
Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease.
5:12-17.
2022
-
Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine-n-butylbromide (Buscopan) During Gastrointestinal Endoscopy.
4:259-268.
2021
-
Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis: A Qualitative Assessment of Patient Perceptions and Experiences.
4:e120-e129.
2021
-
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy.
4:S10-S19.
2021
-
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary.
4:S1-S9.
2021
-
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care.
4:S61-S67.
2021
-
Clinical and Laboratory Characteristics Are Associated With Biologic Therapy Use in Pediatric Inflammatory Bowel Disease: A Retrospective Cohort Study.
4:e92-e100.
2021
-
Declining Use of Corticosteroids for Crohn’s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial.
4:214-221.
2021
-
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines.
161:681-700.
2021
-
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines.
4:e59-e71.
2021
-
Role ofN-Acetylcysteine in the Treatment of Acute Nonacetaminophen, Nonalcoholic and Nonviral Hepatitis: A Meta-analysis.
4:125-130.
2021
-
Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results.
4:84-90.
2021
-
A13 A HIGH SALT DIET SYNERGIZES WITH UC MICROBIOTA TO INDUCE A PROINFLAMMATORY IMMUNE TONE IN IMMUNOCOMPETENT GNOTOBIOTIC MICE.
4:15-16.
2021
-
A232 AUTONOMIC FUNCTION ANALYSIS VIA HEART RATE VARIABILITY ASSOCIATED WITH PROPULSIVE MOTOR PATTERNS OF THE HUMAN COLON.
4:280-282.
2021
-
A235 EFFECTS OF SACRAL PHOTOBIOMODULATION ON THE AUTONOMIC NERVOUS SYSTEM IN PATIENTS WITH COLONIC DYSMOTILITY.
4:284-285.
2021
-
A238 ABSENCE OF AGE-RELATED MEMORY DECLINE IN GERM-FREE MICE.
4:288-289.
2021
-
A29 NOVEL FECAL BIOMARKERS THAT PRECEDE CLINICAL DIAGNOSIS OF ULCERATIVE COLITIS.
4:268-269.
2021
-
A35 ASSOCIATIONS BETWEEN AUTONOMIC DYSFUNCTION, COLONIC DYSMOTILITY AND ABSENT DEFECATION REFLEXES IN PATIENTS WITH CHRONIC REFRACTORY CONSTIPATION.
4:276-278.
2021
-
A39 CULTURE-ENRICHED METAGENOMICS REVEALED MICROBIAL ENGRAFTMENT FOLLOWING FMT IN PATIENTS WITH ULCERATIVE COLITIS.
4:269-270.
2021
-
A4 THE CIRCADIAN TIMING OF INFLAMMATORY BOWEL DISEASE.
4:4-5.
2021
-
A47 SYNTHETIC HUMAN MILK OLIGOSACCHARIDES PREVENT EXPERIMENTAL NECROTIZING ENTEROCOLITIS VIA DIVERGENT TRANSCRIPTOMIC RESPONSES..
4:272-274.
2021
-
A51 ENTERIC PARASITE INFECTION-INDUCED ALTERATION OF THE GUT MICROBIOTA REGULATES INTESTINAL GOBLET CELL BIOLOGY AND MUCIN PRODUCTION VIA TLR2 SIGNALING.
4:7-8.
2021
-
A8 DIETARY TRYPTOPHAN MODULATES KYNURENINE AND INDOLE PRODUCTION IN HEALTHY INDIVIDUALS.
4:9-10.
2021
-
A9 DORSAL ROOT GANGLIA NEURONAL RESPONSES AND SUBSTANCE P PRODUCTION ARE HIGHER IN MALE MICE.
4:10-11.
2021
-
A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease.
4:48-48.
2021
-
COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology.
4:49-49.
2021
-
Clinical Management of the Microbiome in Irritable Bowel Syndrome.
4:36-43.
2021
-
Erratum.
4:50-50.
2021
-
The Defecation Reflex Assessed by High-Resolution Colonic Manometry.
4:1-2.
2021
-
An Electronic Clinical Decision-Making Tool for Patients with Suspected Colorectal Cancer—Preliminary Evaluation in Patients Presenting with Rectal Bleeding.
3:204-209.
2020
-
COVID-19: Framework for the Resumption of Endoscopic Activities From the Canadian Association of Gastroenterology.
3:243-245.
2020
-
Canadian Association of Gastroenterology Communique: After-Hours Endoscopy Cart.
3:222-227.
2020
-
Directly Mailing gFOBT Kits to Previous Responders Being Recalled for Colorectal Cancer Screening Increases Participation.
3:197-203.
2020
-
Propofol Use for Sedation in Endoscopic Procedures: Too Many Physicians in the Room?.
3:151-152.
2020
-
COVID-19: Advice from the Canadian Association of Gastroenterology for Endoscopy Facilities, as of March 16, 2020.
3:147-149.
2020
-
Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease.
3:98-99.
2020
-
The Gluten Free Diet: Assessing Adherence in a Pediatric Celiac Disease Population.
3:67-73.
2020
-
Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness.
3:74-82.
2020
-
A103 PROBIOTIC FORMULATIONS DIFFERENTIALLY AFFECT DISEASE OUTCOME IN A MOUSE MODEL OF NECROTIZING ENTEROCOLITIS.
3:119-120.
2020
-
A108 PROBIOTICS FOR CELIAC DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.
3:125-126.
2020
-
A11 MICROBIAL AND METABOLOMIC PROFILES IDENTIFY SUBSETS OF DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME.
3:13-15.
2020
-
A118 GUT MICROBIOTA TRANSPLANTATION FROM A PATIENT WITH SEVERE CONSTIPATION INDUCED CHANGES IN COLONIC FUNCTION AND STRUCTUR OF GNOTOBIOTIC MICE.
3:137-138.
2020
-
A120 INFLUENCE OF THE MICROBIOTA ON THE POSTNATAL DEVELOPMENT OF THE ENTERIC NERVOUS SYSTEM IS DEPENDENT ON MOUSE STRAIN.
3:140-141.
2020
-
A121 SILENCING ENTERIC SENSORY NEURONS ABOLISHES THE EXCITATORY EFFECT OF SERTRALINE ON VAGAL AFFERENTS.
3:141-142.
2020
-
A122 THE INFLUENCE OF SEX AND THE GUT MICROBIOTA ON VISCERAL PAIN SENSITIVITY IN MICE.
3:142-143.
2020
-
A131 MALNUTRITION FOLLOWING IMPLEMENTATION OF A STRICT LOW FODMAP DIET FOR IBS.
3:151-152.
2020
-
A146 MANAGEMENT OF ANTITHROMBOTIC THERAPY AFTER GASTROINTESTINAL BLEEDING: A MIXED METHODS STUDY OF HEALTHCARE PROVIDERS.
3:9-10.
2020
-
A173 RECOGNIZING RARE PRESENTATIONS OF POLYPOSIS SYNDROMES AND THEIR ASSOCIATED MALIGNANCIES IN PEDIATRIC PATIENTS.
3:38-39.
2020
-
A19 NOVEL HLA-DQ2 TRANSGENIC MICE DEVELOP GLUTEN-IMMUNOPATHOLOGY FOLLOWING GLUTEN SENSITIZATION.
3:22-23.
2020
-
A191 EFFICIENCY OF TAILORED ERADICATION REGIMEN BASED ON ANTIBIOTIC SUSCEPTIBILITY AND CYP2C19 GENOTYPE TESTING IN CHILDREN WITH REFRACTORY HELICOBACTER PYLORI INFECTION.
3:62-63.
2020
-
A193 GLUTEN-FREE DIET IMPROVES DYSPEPSIA-LIKE SYMPTOMS IN A PILOT STUDY OF PATIENTS WITH TYPE 1 DIABETES MELLITUS.
3:64-65.
2020
-
A194 PRESENCE OF CELIAC DISEASE IN PATIENTS WITH BARRETT’S ESOPHAGUS IS ASSOCIATED WITH FASTER DEVELOPMENT OF DYSPLASIA AND HIGHER RATES OF ESOPHAGEAL ADENOCARCINOMA.
3:65-66.
2020
-
A197 MEDICAL INTERVENTIONS IN EOSINOPHILIC ESOPHAGITIS (EOE): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS).
3:70-71.
2020
-
A200 HUMANIZED CELIAC-PRONE EPITHELIUM IN VITRO EXPRESS MHC-II AND CO-STIMULATORY MOLECULES NECESSARY FOR GLUTEN PEPTIDE PRESENTATION.
3:73-74.
2020
-
A209 ROLE OF SEROTONIN-AUTOPHAGY AXIS IN REGULATION OF EPITHELIAL CELL FUNCTION AND MICROBIOTA COMPOSITION IN GUT.
3:81-82.
2020
-
A210
ADLERCREUTZIA IS DEPLETED IN UC PATIENTS, EVEN BEFORE CLINICAL DIAGNOSIS, AND INVERSELY CORRELATES WITH FECAL ELASTOLYTIC ACTIVITY.
3:82-83.
2020
-
A219 PROTECTIVE EFFECTS OF AKKERMANSIA MUCINIPHILA ON INTESTINAL BARRIER FUNCTION AND INFLAMMATION.
3:93-94.
2020
-
A22 ADVERSE EARLY LIFE EVENTS ARE COMMON IN PATIENTS WITH FUNCTIONAL AND ORGANIC GASTROINTESTINAL DISORDERS.
3:26-27.
2020
-
A226 CHILD AND PARENT PERCEPTIONS OF FAECAL MICROBIOTA TRANSPLANT (FMT): QUALITATIVE PERSPECTIVES FROM PARTICIPANTS IN A TRIAL OF FMT FOR PEDIATRIC ULCERATIVE COLITIS.
3:101-102.
2020
-
A227 RESULTS OF THE FIRST PAEDIATRIC RANDOMIZED-CONTROLLED PILOT STUDY OF FAECAL MICROBIOTA TRANSPLANT FOR ACTIVE ULCERATIVE COLITIS (PEDIFETCH TRIAL).
3:102-103.
2020
-
A23 NUTRITIONAL DEFICIENCIES ARE FREQUENT IN CELIAC PATIENTS ON A GLUTEN-FREE DIET, REGARDLESS OF THE DURATION AND COMPLIANCE OF THE DIET.
3:27-28.
2020
-
A242 EXERCISE AND PHYSICAL ACTIVITY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND RECOMMENDATIONS.
3:119-120.
2020
-
A261 MICROBIOTA PROFILES OF PATIENTS WITH MENTAL DISODERS DIFFER FROM THOSE OF HEALTHY CONTROLS.
3:138-139.
2020
-
A35 MICROBIAL PROTEOLYTIC SIGNATURE IN ULCERATIVE COLITIS INDUCES AN INFLAMMATORY SIGNATURE IN MICROBIOTA-HUMANIZED MICE.
3:42-43.
2020
-
A42 MICROBIAL METABOLISM OF DIETARY TRYPTOPHAN ENHANCES ARYL HYDROCARBON RECEPTOR ACTIVATION: IMPLICATIONS FOR IBD.
3:50-51.
2020
-
A43 β-DEFENSINS AS MARKERS OF INTESTINAL DYSBIOSIS: THE NATURE OF CHANGES IN β-DEFENSINS IS DEPENDENT ON THE PROCESS UNDERLYING THE INDUCTION OF DYSBIOSIS.
3:51-52.
2020
-
A45 INFLAMMATION AND INTESTINAL PERMEABILITY IN PEDIATRIC SHORT BOWEL SYNDROME.
3:53-54.
2020
-
A48 COLITIS FAVORS THE EXPANSION OF BACTERIA THAT ACTIVATE PAR2 AMPLIFYING INFLAMMATORY RESPONSE.
3:56-58.
2020
-
A50 TRANSFER OF DEPRESSIVE-LIKE PHENOTYPE TO GNOTOBIOTIC MICE DEPENDS ON MICROBIAL FEATURES SPECIFIC TO INDIVIDUAL PATIENTS.
3:59-60.
2020
-
A53 SACCHAROMYCES BOULARDII CNCM I-745 IMPROVES ANXIETY-LIKE BEHAVIOR AND RESCUES DYSMOTILITY IN A HUMANIZED MOUSE MODEL OF IRRITABLE BOWEL SYNDROME WITH CO-MORBID ANXIETY.
3:62-63.
2020
-
A55 LACK OF EXPERIMENTAL REPRODUCIBILITY IN PRECLINICAL RESEARCH IS INFLUENCED BY THE NUTRITIONAL PROFILE OF STANDARD RODENT CHOWS.
3:64-65.
2020
-
A11 MICROBIAL AND METABOLOMIC PROFILES IDENTIFY SUBSETS OF DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME.
3:13-15.
2020
-
A118 GUT MICROBIOTA TRANSPLANTATION FROM A PATIENT WITH SEVERE CONSTIPATION INDUCED CHANGES IN COLONIC FUNCTION AND STRUCTUR OF GNOTOBIOTIC MICE.
3:137-138.
2020
-
A122 THE INFLUENCE OF SEX AND THE GUT MICROBIOTA ON VISCERAL PAIN SENSITIVITY IN MICE.
3:142-143.
2020
-
A173 RECOGNIZING RARE PRESENTATIONS OF POLYPOSIS SYNDROMES AND THEIR ASSOCIATED MALIGNANCIES IN PEDIATRIC PATIENTS.
3:38-39.
2020
-
A191 EFFICIENCY OF TAILORED ERADICATION REGIMEN BASED ON ANTIBIOTIC SUSCEPTIBILITY AND CYP2C19 GENOTYPE TESTING IN CHILDREN WITH REFRACTORY HELICOBACTER PYLORI INFECTION.
3:62-63.
2020
-
A226 CHILD AND PARENT PERCEPTIONS OF FAECAL MICROBIOTA TRANSPLANT (FMT): QUALITATIVE PERSPECTIVES FROM PARTICIPANTS IN A TRIAL OF FMT FOR PEDIATRIC ULCERATIVE COLITIS.
3:101-102.
2020
-
A227 RESULTS OF THE FIRST PAEDIATRIC RANDOMIZED-CONTROLLED PILOT STUDY OF FAECAL MICROBIOTA TRANSPLANT FOR ACTIVE ULCERATIVE COLITIS (PEDIFETCH TRIAL).
3:102-103.
2020
-
A242 EXERCISE AND PHYSICAL ACTIVITY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND RECOMMENDATIONS.
3:119-120.
2020
-
A261 MICROBIOTA PROFILES OF PATIENTS WITH MENTAL DISODERS DIFFER FROM THOSE OF HEALTHY CONTROLS.
3:138-139.
2020
-
A43 β-DEFENSINS AS MARKERS OF INTESTINAL DYSBIOSIS: THE NATURE OF CHANGES IN β-DEFENSINS IS DEPENDENT ON THE PROCESS UNDERLYING THE INDUCTION OF DYSBIOSIS.
3:51-52.
2020
-
A50 TRANSFER OF DEPRESSIVE-LIKE PHENOTYPE TO GNOTOBIOTIC MICE DEPENDS ON MICROBIAL FEATURES SPECIFIC TO INDIVIDUAL PATIENTS.
3:59-60.
2020
-
A53 SACCHAROMYCES BOULARDII CNCM I-745 IMPROVES ANXIETY-LIKE BEHAVIOR AND RESCUES DYSMOTILITY IN A HUMANIZED MOUSE MODEL OF IRRITABLE BOWEL SYNDROME WITH CO-MORBID ANXIETY.
3:62-63.
2020
-
A55 LACK OF EXPERIMENTAL REPRODUCIBILITY IN PRECLINICAL RESEARCH IS INFLUENCED BY THE NUTRITIONAL PROFILE OF STANDARD RODENT CHOWS.
3:64-65.
2020
-
Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea.
3:e10-e27.
2020
-
Development of a Global Rating Scale for Inflammatory Bowel Disease.
3:4-16.
2020
-
Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease.
3:e1-e9.
2020
-
Anxiety, Depression and Quality of Life Improve After One Month and Three Months of Home Parenteral Nutrition: A Pilot Study in a Canadian Population.
2:178-185.
2019
-
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary.
2:149-152.
2019
-
An Actively Bleeding Lesion in Video Capsule Endoscopy Study as a Source of Occult Gastrointestinal Bleeding.
2:99-100.
2019
-
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease.
2:e1-e34.
2019
-
Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease.
2:e35-e63.
2019
-
Characterization of Serotonin Signaling Components in Patients with Inflammatory Bowel Disease.
2:132-140.
2019
-
The Benefit of Fentanyl in Effective Sedation and Quality of Upper Endoscopy: A Double-Blinded Randomized Trial of Fentanyl Added to Midazolam Versus Midazolam Alone for Sedation.
2:86-90.
2019
-
A136 A LONGITUDINAL STUDY EXAMINING FODMAP INTAKE AND THE METABOLOME IN IBS PATIENTS.
2:271-272.
2019
-
A139 A LOW FODMAP DIET REDUCES SYMPTOMS IN INDIVIDUAL IBS PATIENTS BUT NOT MUCOSAL IMMUNE ACTIVATION OF NOCICEPTORS.
2:277-278.
2019
-
A149 EARLY LIFE EVENTS IN PATIENTS WITH CELIAC DISEASE ARE COMMON AND ASSOCIATE WITH SEVERITY OF CONSTIPATION IN ADULTHOOD..
2:296-296.
2019
-
A152 D-LACTIC ACIDOSIS IN CHILDREN WITH SHORT BOWEL SYNDROME-A LITERATURE REVIEW AND REPORT OF TWO CASES.
2:301-302.
2019
-
A173 LACK OF EXPERIMENTAL REPRODUCIBILITY IN PRECLINICAL RESEARCH: FOCUS ON DIETARY CONTENT OF FERMENTABLE CARBOHYDRATE (FODMAPS) IN STANDARD RODENT CHOWS.
2:340-341.
2019
-
A241 APPLICATION OF NEXT GENERATION QUALITY AND EXPERT-LED CASE REVIEW TO INCREASE THE CONSISTENCY OF SESSILE SERRATED ADENOMA DIAGNOSTIC RATES: A CANADIAN TERTIARY-CARE CENTRE EXPERIENCE.
2:472-473.
2019
-
A32 THE ROLE OF GUT MICROBIOTA AND TRACE AMINES IN A MURINE MODEL OF GENERALIZED ANXIETY DISORDER.
2:64-65.
2019
-
A33 ROLE OF SEROTONIN-AUTOPHAGY AXIS IN INTESTINAL INFLAMMATION.
2:66-67.
2019
-
A38 DIETARY FODMAP CONTENT MODULATES FERMENTATION PATTERNS IN PRECLINICAL MODELS OF IBD BUT DOES NOT EXACERBATE OVERT INFLAMMATION.
2:76-77.
2019
-
A4 INVESTIGATING MICROBIAL ENGRAFTMENT VIA A COMPREHENSIVE CULTURE-ENRICHED AND CULTURE-INDEPENDENT METAGENOMICS IN PATIENTS WITH ULCERATIVE COLITIS.
2:9-10.
2019
-
A46 FECAL β-DEFENSIN LEVELS AS A RELIABLE BIOMARKER OF INTESTINAL DYSBIOSIS.
2:92-93.
2019
-
A48 NOVEL INTESTINAL ORGANOID-DERIVED MONOLAYERS TO MODEL CELIAC EPITHELIUM IN VITRO.
2:96-96.
2019
-
A49 LACTOBACILLI DEGRADE WHEAT AMYLASE TRYPSIN INHIBITORS (ATI) TO AMELIORATE GUT DYSFUNCTION INDUCED BY IMMUNOGENIC WHEAT PROTEINS.
2:97-98.
2019
-
A50 MICROBIOTA-MAST CELL INTERACTIONS IN A HUMANIZED MOUSE MODEL OF IBS.
2:99-100.
2019
-
A59 EXPLORING THE ROLE OF MICROBIOTA IN GASTROINTESTINAL MOTILITY.
2:118-119.
2019
-
A152 D-LACTIC ACIDOSIS IN CHILDREN WITH SHORT BOWEL SYNDROME-A LITERATURE REVIEW AND REPORT OF TWO CASES.
2:301-302.
2019
-
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS).
2:6-29.
2019
-
Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders.
2:37-43.
2019
-
Patient Engagement and Multidisciplinary Involvement Has an Impact on Clinical Guideline Development and Decisions: A Comparison of Two Irritable Bowel Syndrome Guidelines Using the Same Data.
2:30-36.
2019
-
Resident Survey on Gastroenterology Training in Canada.
2:44-48.
2019
-
Canadian Association of Gastroenterology Statement on the Putative Link
Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter
pylori Eradication.
1:155-158.
2018
-
Clinical Practice Guideline for the Medical Management of Perianal
Fistulizing Crohn’s Disease: The Toronto Consensus.
1:141-154.
2018
-
Impact of Adalimumab Patient Support Program’s Care Coach Calls on Clinical
Outcomes in Patients with Crohn’s Disease in Canada: An Observational Retrospective Cohort
Study.
1:191-198.
2018
-
Rectal Indomethacin Prevents Moderate to Severe Post-ERCP Pancreatitis and Death and Should Be Used Before the Procedure: A Meta-Analysis of Aggregate Subgroup Data.
1:67-75.
2018
-
Clinical Practice Guidelines for the Assessment of Uninvestigated Esophageal Dysphagia.
1:5-19.
2018
-
Journal of the Canadian Association of Gastroenterology.
1:1-1.
2018
-
A115 ROLE OF GUT SEROTONIN IN ANTIMICROBIAL PEPTIDE PRODUCTION.
1:203-203.
2018
-
A118 EXPOSURE TO CROHN’S DISEASE-ASSOCIATED ADHERENT-INVASIVE E.COLI (AIEC) AT THE HEIGHT OF INFECTIOUS COLITIS IMPAIRS HOST-MEDIATED CLEARANCE OF AIEC.
1:208-208.
2018
-
A13 PROTEOLYTIC BACTERIA PROMOTE INNATE IMMUNE ACTIVATION AND GLUTEN-INDUCED PATHOLOGY IN MICE..
1:23-24.
2018
-
A153 MEASURING QUALITY OF LIFE AND DISEASE ACTIVITY IN PEDIATRIC PATIENTS RECEIVING INDUCTION THERAPY OF EXCLUSIVE ENTERAL NUTRITION OR CORTICOSTEROIDS FOR ACTIVE INFLAMMATORY BOWEL DISEASE.
1:264-265.
2018
-
A19 BACTERIAL PROTEASES INCREASE SENSITIVITY TO DIETARY ANTIGEN THROUGH PAR-2 SIGNALING.
1:31-32.
2018
-
A20 GUT MICROBIOTA-DIET INTERACTION ALTER INTESTINAL MAST CELL NUMBERS AND DISTRIBUTION IN THE HUMANIZED IBS MOUSE MODEL.
1:33-34.
2018
-
A21 FERMENTABLE CARBOHYDRATE-MICROBIOME INTERACTIONS IN A MOUSE MODEL OF IBS.
1:35-36.
2018
-
A235 EXPLORING PATIENT FACTORS FOR CANCELLED OR MISSED APPOINTMENTS TO AN URGENT GASTROENTEROLOGY OUTPATIENT CLINIC..
1:345-345.
2018
-
A236 UTILIZATION OF AN URGENT GASTROENTEROLOGY CLINIC FOR PATIENTS SEEN IN THE EMERGENCY ROOM OR URGENT CARE CENTRE.
1:346-346.
2018
-
A237 COLONOSCOPY PREPARATION OPTIMIZATION FOR INPATIENTS (COIN STUDY). A RANDOMIZED CONTROLLED TRIAL COMPARING 4L PEGLYTE TO REGULAR DOSE PICO SALAX AND SPLIT DOSE PICO SALAX FOR COLONOSCOPY BOWEL PREPARATION IN HOSPITALIZED PATIENTS..
1:347-347.
2018
-
A263 IBS-D MICROBIOTA INDUCES GUT-BRAIN DYSFUNCTION BY DISRUPTING INTESTINAL NEURAL AND IMMUNE PATHWAYS.
1:458-458.
2018
-
A266 AMYLASE TRYPSIN INHIBITORS FROM WHEAT EXACERBATE GLUTEN-INDUCED PATHOLOGY AND ALTER GUT MICROBIOTA IN MICE.
1:462-462.
2018
-
A274 GUT MICROBIOTA REGULATES INNATE EPITHELIAL RESPONSES AGAINST AN ENTERIC BACTERIAL PATHOGEN.
1:396-396.
2018
-
A276 CHARACTERIZING MICROBIOTA COMPOSITION AND FUNCTION THAT PRECEDE DEVELOPMENT OF CLINICALLY RELEVANT INFLAMMATION IN UC PATIENTS.
1:399-400.
2018
-
A278 ESCHERICHIA ABUNDANCE AND LOW FECAL BUTYRATE IN CHILDREN WITH INTESTINAL FAILURE.
1:402-403.
2018
-
A279 COLONIZATION WITH PROTEOLYTIC BACTERIA INDUCES LOW-GRADE INFLAMMATION AND BARRIER DYSFUNCTION IN MICE.
1:404-404.
2018
-
A281 EFFECT OF A GLUTEN FREE DIET ON SYMPTOMS IN IBS PATIENTS STRATIFIED BY ANTIGLIADIN ANTIBODIES.
1:488-488.
2018
-
A284 CHARACTERIZING SIMULTANEOUS PRESSURE WAVES IN THE HUMAN COLON BY HIGH-RESOLUTION MANOMETRY.
1:409-410.
2018
-
A287 REACTIVITY OF THE EXTRINSIC AUTONOMIC NERVOUS SYSTEM ASSOCIATED WITH HUMAN COLONIC MOTOR PATTERNS.
1:413-414.
2018
-
A288 ANAL SPHINCTER RELAXATION ASSOCIATED WITH THE DEFECATION REFLEX AND GAS EXPULSION, ASSESSED BY HIGH-RESOLUTION COLONIC MANOMETRY.
1:415-416.
2018
-
A288 DISTINCT ROLES IN INNATE HOST DEFENSE AND SUSCEPTIBILITY TO COLONIC INJURY IN MUC2 MUCIN DEFICIENT AND SUFFICIENT MICROBIOTA.
1:499-500.
2018
-
A291 INVESTIGATING THE ROLE OF ANTIBIOTICS AND ADHERENT-INVASIVE E. COLI
IN THE PATHOGENESIS OF CROHN’S DISEASE.
1:505-505.
2018
-
A293 SQUALAMINE INCREASES VAGAL AFFERENT FIRING FREQUENCY IN AGING MICE.
1:421-421.
2018
-
A294 NORADRENALINE INHIBITS PROPULSIVE MOTOR PATTERNS BUT NOT SEGMENTING HAUSTRAL PROGRESSION IN THE RABBIT 3-TAENIATED COLON.
1:422-423.
2018
-
A294 ROLE OF MACROPHAGE IN GUT MICROBIOTA-BRAIN SIGNALING.
1:510-510.
2018
-
A295 FUCOSE AVAILABILITY AND ITS UTILIZATION IMPACT IN VIVO
ENTERIC PATHOGEN VIRULENCE..
1:511-512.
2018
-
A296 A RHYTHMIC MOTOR PATTERN ASSOCIATED WITH HIGH AMPLITUDE PRESSURE WAVES IN HUMAN HIGH-RESOLUTION COLONIC MANOMETRY.
1:425-426.
2018
-
A297 FREQUENT ADVERSE CHILDHOOD EVENTS IN PATIENTS WITH IBS AND ORGANIC GASTROINTESTINAL DISORDERS.
1:427-427.
2018
-
A3 A SERPIN-PRODUCING BIFIDOBACTERIA IMPROVES GLUTEN PATHOLOGY IN MICE.
1:4-5.
2018
-
A300 DIET-MICROBIOTA INTERACTIONS UNDERLIE SYMPTOMS IN IBS.
1:521-522.
2018
-
A301 ANTIBIOTICS INCREASE VAGAL AFFERENT FIRING IN THE MOUSE JEJUNUM.
1:432-432.
2018
-
A301 GUT MICROBIOTA FROM A PATIENT WITH GENERALIZED ANXIETY DISORDER INDUCES ANXIETY-LIKE BEHAVIOUR AND ALTERED BRAIN CHEMISTRY IN GNOTOBIOTIC MICE.
1:523-524.
2018
-
A302 LUMINAL SHORT-CHAIN FATTY ACIDS RESTORE MOTILITY IN GERM-FREE MICE.
1:525-526.
2018
-
A303 SIMULTANEOUS PRESSURE WAVES ARE A KEY COMPONENT OF HUMAN COLON MOTOR FUNCTION ASSESSMENT, USING HIGH-RESOLUTION COLONIC MANOMETRY (HRCM).
1:527-528.
2018
-
A306 LACTOBACILLUS RHAMNOSUS
JB-1 AMELIORATES COLONIC AGE-RELATED DYSMOTILITY.
1:531-532.
2018
-
A307 EFFECT OF SLOW SYNAPTIC EXCITATION ON MYENTERIC INTRINSIC PRIMARY AFFERENT NEURON BKCA CHANNEL ACTIVITY.
1:533-533.
2018
-
A309 ANTIBIOTIC DRIVEN CHANGES IN GUT MOTILITY HIGHLIGHT DIRECT MODULATION OF ENTERIC NERVOUS SYSTEM.
1:536-536.
2018
-
A330 PREVENTION OF POST-ERCP PANCREATITIS: DO PROTEASE INHIBITORS HAVE A ROLE?.
1:475-476.
2018
-
A67 RAPID REDUCTION IN ANXIETY SCORES IN IBD PATIENTS AFTER INFLIXIMAB INFUSION IS ASSOCIATED WITH CHANGES IN KYNURENINE/TRYPTOPHAN METABOLISM.
1:106-106.
2018
-
A8 INFLUENCE OF MATERNAL SSRI EXPOSURE ON THE DEVELOPMENT OF THE ENTERIC NERVOUS SYSTEM.
1:12-12.
2018
-
A8 PROLONGED FASTING ALTERS THE GUT MICROBIOME AND PROTECTS AGAINST SALMONELLA
-INDUCED GUT INFLAMMATION.
1:14-15.
2018
-
A84 INTERACTION OF SEROTONIN WITH PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-GAMMA IN ANTIMICROBIAL PEPTIDE PRODUCTION IN GUT.
1:128-128.
2018
-
A153 MEASURING QUALITY OF LIFE AND DISEASE ACTIVITY IN PEDIATRIC PATIENTS RECEIVING INDUCTION THERAPY OF EXCLUSIVE ENTERAL NUTRITION OR CORTICOSTEROIDS FOR ACTIVE INFLAMMATORY BOWEL DISEASE.
1:264-265.
2018
-
Real-life management of chronic hepatitis C virus infection in Canada: Description of patient profile, prognostic factors and treatment strategies.
1:326-328.
2018
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)